PANORAMA-1 Trial in Multiple Myeloma: Patient-Reported Outcomes With Panobinostat
Posted: Friday, June 22, 2018
According to Paul G. Richardson, MD, of Dana-Farber Cancer Institute, Boston, and colleagues, not only is the addition of panobinostat to the bortezomib plus dexamethasone regimen an effective treatment option for patients with have already received therapy for multiple myeloma, it appears to result in “limited symptomatology and impact on patients’ quality of life.” These findings, which were published in the British Journal of Haematology, are from the patient-reported outcomes analysis of the international phase III PANORAMA-1 trial, the study that led to regulatory approvals of this regimen in this patient population.
The investigators performed a descriptive analysis of data on patient-reported outcomes from 73 patients in the panobinostat combination therapy arm and 74 patients in the placebo combination therapy arm (bortezomib and dexamethasone alone). The measures used were the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire-Core 30 (EORTC QLQ-C30), the EORTC QLQ-Myeloma module (EORTC QLQ-MY20), and the Functional Assessment of Cancer Therapy/Gynecology Oncology Group–Neurotoxicity (FACT-GOG-Ntx).
During the first 24 weeks of therapy, the global health status/quality of life scores per the EORTC QLQ-C30 initially declined with the use of panobinostat. However, the scores then approached baseline scores and “remained steady” over the next 24 weeks; no difference was reported between the treatment groups at 48 weeks. Disease symptom scores in both treatment arms initially improved and subsequently stabilized, based on the EORTC QLQ-MY20. Similar FACT-GOG-Ntx scores were observed in both treatment groups.
